The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global PD-1 and PD-L1 Inhibitors Market Research Report 2025

Global PD-1 and PD-L1 Inhibitors Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1541895

No of Pages : 93

Ask Your Query
Synopsis
PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.
The global PD-1 and PD-L1 Inhibitors market was valued at US$ 39550 million in 2023 and is anticipated to reach US$ 145420 million by 2030, witnessing a CAGR of 20.2% during the forecast period 2024-2030.
North America is the largest consumption place, with a consumption market share nearly 60.40% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 20.66%.Market competition is intense. Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical etc. are the leaders of the industry.
This report aims to provide a comprehensive presentation of the global market for PD-1 and PD-L1 Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-1 and PD-L1 Inhibitors.
Report Scope
The PD-1 and PD-L1 Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (L) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global PD-1 and PD-L1 Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PD-1 and PD-L1 Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Bristol-Myers Squibb
Roche
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Merck KGaA
Segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors
Segment by Application
Solid Tumors
Blood-related Tumors
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of PD-1 and PD-L1 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of PD-1 and PD-L1 Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index
1 PD-1 and PD-L1 Inhibitors Market Overview
1.1 Product Overview and Scope of PD-1 and PD-L1 Inhibitors
1.2 PD-1 and PD-L1 Inhibitors Segment by Type
1.2.1 Global PD-1 and PD-L1 Inhibitors Market Value Comparison by Type (2024-2030)
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.3 PD-1 and PD-L1 Inhibitors Segment by Application
1.3.1 Global PD-1 and PD-L1 Inhibitors Market Value by Application: (2024-2030)
1.3.2 Solid Tumors
1.3.3 Blood-related Tumors
1.4 Global PD-1 and PD-L1 Inhibitors Market Size Estimates and Forecasts
1.4.1 Global PD-1 and PD-L1 Inhibitors Revenue 2019-2030
1.4.2 Global PD-1 and PD-L1 Inhibitors Sales 2019-2030
1.4.3 Global PD-1 and PD-L1 Inhibitors Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 PD-1 and PD-L1 Inhibitors Market Competition by Manufacturers
2.1 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Manufacturers (2019-2024)
2.2 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Manufacturers (2019-2024)
2.3 Global PD-1 and PD-L1 Inhibitors Average Price by Manufacturers (2019-2024)
2.4 Global PD-1 and PD-L1 Inhibitors Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of PD-1 and PD-L1 Inhibitors, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of PD-1 and PD-L1 Inhibitors, Product Type & Application
2.7 PD-1 and PD-L1 Inhibitors Market Competitive Situation and Trends
2.7.1 PD-1 and PD-L1 Inhibitors Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest PD-1 and PD-L1 Inhibitors Players Market Share by Revenue
2.7.3 Global PD-1 and PD-L1 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 PD-1 and PD-L1 Inhibitors Retrospective Market Scenario by Region
3.1 Global PD-1 and PD-L1 Inhibitors Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global PD-1 and PD-L1 Inhibitors Global PD-1 and PD-L1 Inhibitors Sales by Region: 2019-2030
3.2.1 Global PD-1 and PD-L1 Inhibitors Sales by Region: 2019-2024
3.2.2 Global PD-1 and PD-L1 Inhibitors Sales by Region: 2025-2030
3.3 Global PD-1 and PD-L1 Inhibitors Global PD-1 and PD-L1 Inhibitors Revenue by Region: 2019-2030
3.3.1 Global PD-1 and PD-L1 Inhibitors Revenue by Region: 2019-2024
3.3.2 Global PD-1 and PD-L1 Inhibitors Revenue by Region: 2025-2030
3.4 North America PD-1 and PD-L1 Inhibitors Market Facts & Figures by Country
3.4.1 North America PD-1 and PD-L1 Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America PD-1 and PD-L1 Inhibitors Sales by Country (2019-2030)
3.4.3 North America PD-1 and PD-L1 Inhibitors Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe PD-1 and PD-L1 Inhibitors Market Facts & Figures by Country
3.5.1 Europe PD-1 and PD-L1 Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe PD-1 and PD-L1 Inhibitors Sales by Country (2019-2030)
3.5.3 Europe PD-1 and PD-L1 Inhibitors Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific PD-1 and PD-L1 Inhibitors Market Facts & Figures by Country
3.6.1 Asia Pacific PD-1 and PD-L1 Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Country (2019-2030)
3.6.3 Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America PD-1 and PD-L1 Inhibitors Market Facts & Figures by Country
3.7.1 Latin America PD-1 and PD-L1 Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America PD-1 and PD-L1 Inhibitors Sales by Country (2019-2030)
3.7.3 Latin America PD-1 and PD-L1 Inhibitors Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa PD-1 and PD-L1 Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa PD-1 and PD-L1 Inhibitors Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Country (2019-2030)
3.8.3 Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global PD-1 and PD-L1 Inhibitors Sales by Type (2019-2030)
4.1.1 Global PD-1 and PD-L1 Inhibitors Sales by Type (2019-2024)
4.1.2 Global PD-1 and PD-L1 Inhibitors Sales by Type (2025-2030)
4.1.3 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2019-2030)
4.2 Global PD-1 and PD-L1 Inhibitors Revenue by Type (2019-2030)
4.2.1 Global PD-1 and PD-L1 Inhibitors Revenue by Type (2019-2024)
4.2.2 Global PD-1 and PD-L1 Inhibitors Revenue by Type (2025-2030)
4.2.3 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2019-2030)
4.3 Global PD-1 and PD-L1 Inhibitors Price by Type (2019-2030)
5 Segment by Application
5.1 Global PD-1 and PD-L1 Inhibitors Sales by Application (2019-2030)
5.1.1 Global PD-1 and PD-L1 Inhibitors Sales by Application (2019-2024)
5.1.2 Global PD-1 and PD-L1 Inhibitors Sales by Application (2025-2030)
5.1.3 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2019-2030)
5.2 Global PD-1 and PD-L1 Inhibitors Revenue by Application (2019-2030)
5.2.1 Global PD-1 and PD-L1 Inhibitors Revenue by Application (2019-2024)
5.2.2 Global PD-1 and PD-L1 Inhibitors Revenue by Application (2025-2030)
5.2.3 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2019-2030)
5.3 Global PD-1 and PD-L1 Inhibitors Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck PD-1 and PD-L1 Inhibitors Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Bristol-Myers Squibb
6.2.1 Bristol-Myers Squibb Corporation Information
6.2.2 Bristol-Myers Squibb Description and Business Overview
6.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Portfolio
6.2.5 Bristol-Myers Squibb Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Roche PD-1 and PD-L1 Inhibitors Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 AstraZeneca
6.4.1 AstraZeneca Corporation Information
6.4.2 AstraZeneca Description and Business Overview
6.4.3 AstraZeneca PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.4.4 AstraZeneca PD-1 and PD-L1 Inhibitors Product Portfolio
6.4.5 AstraZeneca Recent Developments/Updates
6.5 Ono Pharmaceutical
6.5.1 Ono Pharmaceutical Corporation Information
6.5.2 Ono Pharmaceutical Description and Business Overview
6.5.3 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Portfolio
6.5.5 Ono Pharmaceutical Recent Developments/Updates
6.6 Regeneron
6.6.1 Regeneron Corporation Information
6.6.2 Regeneron Description and Business Overview
6.6.3 Regeneron PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Regeneron PD-1 and PD-L1 Inhibitors Product Portfolio
6.6.5 Regeneron Recent Developments/Updates
6.7 Innovent
6.6.1 Innovent Corporation Information
6.6.2 Innovent Description and Business Overview
6.6.3 Innovent PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Innovent PD-1 and PD-L1 Inhibitors Product Portfolio
6.7.5 Innovent Recent Developments/Updates
6.8 Hengrui Medicine
6.8.1 Hengrui Medicine Corporation Information
6.8.2 Hengrui Medicine Description and Business Overview
6.8.3 Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Portfolio
6.8.5 Hengrui Medicine Recent Developments/Updates
6.9 Junshi Biosciences
6.9.1 Junshi Biosciences Corporation Information
6.9.2 Junshi Biosciences Description and Business Overview
6.9.3 Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Portfolio
6.9.5 Junshi Biosciences Recent Developments/Updates
6.10 Merck KGaA
6.10.1 Merck KGaA Corporation Information
6.10.2 Merck KGaA Description and Business Overview
6.10.3 Merck KGaA PD-1 and PD-L1 Inhibitors Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Merck KGaA PD-1 and PD-L1 Inhibitors Product Portfolio
6.10.5 Merck KGaA Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 PD-1 and PD-L1 Inhibitors Industry Chain Analysis
7.2 PD-1 and PD-L1 Inhibitors Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 PD-1 and PD-L1 Inhibitors Production Mode & Process
7.4 PD-1 and PD-L1 Inhibitors Sales and Marketing
7.4.1 PD-1 and PD-L1 Inhibitors Sales Channels
7.4.2 PD-1 and PD-L1 Inhibitors Distributors
7.5 PD-1 and PD-L1 Inhibitors Customers
8 PD-1 and PD-L1 Inhibitors Market Dynamics
8.1 PD-1 and PD-L1 Inhibitors Industry Trends
8.2 PD-1 and PD-L1 Inhibitors Market Drivers
8.3 PD-1 and PD-L1 Inhibitors Market Challenges
8.4 PD-1 and PD-L1 Inhibitors Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock